首页> 外文期刊>Chinese Jouranl of Integrative Medicine >A Clinical Study of Suogudan Granule in the Treatment of Rheumatoid Arthritis
【24h】

A Clinical Study of Suogudan Granule in the Treatment of Rheumatoid Arthritis

机译:锁骨丹颗粒治疗类风湿关节炎的临床研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To study the clinical efficacy of Suogudan Granule (SGDG) in the treatment of rheumatoid arthritis (RA). Methods: Ninety patients with RA were randomly divided into the treated group and the control group. The treated group was administered orally with SGDG 6 g each time, thrice a day, while the control group with the combined therapy of Fenbid Capsules 0.3 g each time, twice a day and Tripterygium tablet 20 mg each time, thrice a day. The treatment course for both groups was 6 weeks. The changes of clinical symptoms and signs, and laboratory indices such as erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), antistreptolysin O (ASO), routine examination of blood and urine, liver and kidney function, etc. before and after treatment were observed. Results: (1) The total effective rate in the treated group (88.0%) was obviously higher than that in the control group (67.5%) with significant difference (P < 0.05). (2) The improvement in arthralgia, joint swelling, time of morning stiffness, 15-meter walking, analgesia initiation and persistence in the treated group was better than that in the control group (P < 0.05, P < 0.01), but there was no obvious difference in improvement of joint tenderness, range of joint motion, grip strength, and initiating detumescence time ( P > 0.05). (3) The improvement in ESR and RF in the treated group was better than that in the control group with significant difference (P < 0.05). The negative-conversion rate of ASO in the treated group was also higher than that in the control group (P < 0.01). (4) No evident abnormality in blood, urine, liver or kidney function was found in either group. Conclusion: SGDG is effective and safe for the treatment of RA.
机译:目的:研究索固丹颗粒(SGDG)治疗类风湿关节炎(RA)的临床疗效。方法:将90例RA患者随机分为治疗组和对照组。治疗组每天口服三次,每次6g SGDG,对照组每天两次,每次两次口服0.3g芬必得胶囊和雷公藤甲片20mg的联合治疗。两组的疗程均为6周。治疗前后的临床症状和体征变化以及实验室指标如红细胞沉降率(ESR),类风湿因子(RF),抗链球菌溶血素O(ASO),血液和尿液,肝肾功能的常规检查等被观察。结果:(1)治疗组总有效率(88.0%)明显高于对照组(67.5%),差异有统计学意义(P <0.05)。 (2)与对照组相比,治疗组关节痛,关节肿胀,晨僵时间,15米步行,止痛镇痛和持续性的改善均好于对照组(P <0.05,P <0.01)。关节压痛,关节运动范围,握力和起始消肿时间的改善无明显差异(P> 0.05)。 (3)治疗组ESR和RF改善优于对照组,差异有统计学意义(P <0.05)。治疗组ASO的负转化率也高于对照组(P <0.01)。 (4)两组均未发现血液,尿液,肝或肾功能异常。结论:SGDG治疗RA是安全有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号